Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $6.25.

XERS has been the subject of several research analyst reports. Leerink Partners boosted their price objective on Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a report on Friday, March 7th. Wall Street Zen lowered Xeris Biopharma from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Piper Sandler reissued a "neutral" rating and set a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. HC Wainwright restated a "buy" rating and set a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Finally, Craig Hallum lifted their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a report on Friday, March 7th.

Xeris Biopharma Trading Up 2.7%

XERS stock traded up $0.12 during midday trading on Tuesday, hitting $4.58. 1,820,428 shares of the company's stock were exchanged, compared to its average volume of 1,972,475. The firm has a 50 day moving average price of $4.56 and a 200-day moving average price of $4.07. Xeris Biopharma has a 12-month low of $2.03 and a 12-month high of $6.07. The stock has a market capitalization of $716.24 million, a price-to-earnings ratio of -10.18 and a beta of 1.10.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $57.80 million during the quarter, compared to the consensus estimate of $57.61 million. On average, sell-side analysts forecast that Xeris Biopharma will post -0.41 EPS for the current fiscal year.

Insiders Place Their Bets

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the company's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the transaction, the insider now directly owns 1,353,510 shares of the company's stock, valued at $7,349,559.30. This represents a 2.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 6.47% of the company's stock.

Hedge Funds Weigh In On Xeris Biopharma

Hedge funds have recently added to or reduced their stakes in the company. NewEdge Advisors LLC acquired a new stake in Xeris Biopharma in the 4th quarter worth approximately $34,000. R Squared Ltd bought a new position in Xeris Biopharma in the 4th quarter worth $42,000. Cibc World Markets Corp acquired a new position in Xeris Biopharma during the 4th quarter worth $44,000. Raymond James Financial Inc. acquired a new position in Xeris Biopharma during the 4th quarter worth $45,000. Finally, Two Sigma Advisers LP bought a new stake in Xeris Biopharma during the fourth quarter valued at about $47,000. Institutional investors and hedge funds own 42.75% of the company's stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.